Fast-Switching, High-Contrast, Electrochromic Sunwear for Persons with Age-Relate

适合年龄相关人士的快速切换、高对比度、电致变色太阳镜

• 批准号: 8589501
• 负责人: PRASANNA CHANDRASEKHAR
• 金额: $ 53.63万
• 依托单位: ASHWIN-USHAS CORPORATION, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2016-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8589501
• 关键词: Adhesives; Adult; Age; Age related macular degeneration; Aging; Algorithms; Angiogenesis Inhibitors; Automation; Automobiles; Blindness; Characteristics; Coagulation Process; Color; Contracts; Corneal dystrophy; Diabetic Retinopathy; Disease; Electrolytes; Eye diseases; Film; Gel; Glass; Impairment; Implant; Industry; Injection of therapeutic agent; Joints; Lasers; Legal patent; Life; Light; Lucentis; Manufacturer Name; Marketing; Medical; Memory; Operative Surgical Procedures; Optics; Patients; Performance; Personal Satisfaction; Persons; Phase; Photochemotherapy; Plants; Plastics; Polymers; Population; Production; Quality of life; Recovery; Retinitis Pigmentosa; S cerevisiae SWI3 protein; Safety; Skiing; Solid; Solutions; Solvents; Sports; Staging; Syndrome; Technology; Testing; Time; Ultraviolet Rays; Verteporfin; Veterans; Vision; Visual impairment; Weight; Work; age group; age related; aging population; base; commercialization; cost; daily functioning; design; flexibility; improved; indium tin oxide; lens; liquid crystal; miniaturize; monomer; mylar; prototype; public health relevance; ranibizumab; research and development; scale up; solid state; success; sunglasses; vision aid; voltage

DESCRIPTION: Age-Related Macular Degeneration (ARMD) afflicts > 40% of the >60 population. > 70% of US visually impaired population is > 60; within this, ARMD is the largest cause of impairment. A primary feature of ARMD is inability to adapt between light/dark (L/D), leading to loss in functional vision indoors/ outdoors. There is currently no proven, practical, noninvasive-medical or surgical treatment for ARMD applicable to all patients. Current highly inadequate remedies: (1) Multiple layers of sunglasses put on/taken off rapidly between L/D. (2) V. slow-switching photochromics (need UV light for activation, incomplete switching 25-30 s, complete 3-5 min., don't work inside cars/indoors). (3) Expensive anti-angiogenic drugs, low-vision aids, photodynamic therapy (v. limited relief). (4) Surgery, mostly for "end-stage" ARMD, e.g.: telescope implant (only partial vision); laser photo-coagulation (only for non-sub-foveal ARMD); submacular, subretinal surgery (limited success). A solution would greatly improve the quality of life/well-being of the 40% of age >60 adults afflicted with ARMD, as well as persons with other, age-related diseases, e.g. diabetic retinopathy, corneal dystrophy, retinitis pigmentosa, Wagner syndrome, retinoschesis. In earlier work, our group extensively studied age >60 ARMD veterans at Atlanta VA Center, showing they could benefit highly from fast-darkening (< 5 s) electrochromic (EC) glasses based on liquid crystals (LCs), vs. multiple sunglasses/-photochromics; LC glasses however had serious drawbacks. In present Phase I, a breakthrough EC technology based on Conducting Polymers (CPs) was demonstrated with: (1) perfectly matched, complimentarily coloring CPs, yielding typical L/D contrast 70%/10% (380-760 nm, industry-standard algorithm). (2) Inexpensive (< $3) Controller with algorithm yielding switching times > 5X faster than with conventional voltage control (L->D 2 to 4 s, D->L 1 s); fully automated, photosensor control. (3) V. thin, flexible, durable. (4) Cyclability > 10^5 cycles. (5) Excellent optical memory. (6) V. low power (15 uW/cm2, +/- 3.0 VDC). (7) Est. < $27/pair. (8) High current potentiostat developed, (< $200/unit), dramatically reducing manufacture cost. Proposed work will: (1) Complete final tech refinement (mainly lower-resistivity, thinner ITO substrates to dramatically enhance switching time and L/D contrast). (2) Fabricate prototypes of 3 distinct product designs. (3) Optimize by testing on ARMD patients at Atlanta VA Center (75 subjects age > 55, ARMD + other age-related eye diseases). (4) Further miniaturize, manufacture Controller, battery. (5) Complete initial producn. optimizn. studies. (6) Initial pilot plant, 100-glasses-pairs/month. (7) Scale up: 1000 to 10,000 glasses/month, resolve automation issues, est. product costs. (8) Establish relationships with selected contract manufacturers, marketing tie-ups. A successful Phase II will also yield electrochromics that could replace entire photochromics market, thus dramatically lowering costs for ARMD sunglasses. Joint effort with Atlanta VA Rehab R&D Ctr. for Aging Vision Loss, two industrial automation firms, several eyewear distributors.

描述：与年龄有关的黄斑变性（ARMD）苦难> 60％的人口> 40％。 >美国70％的视力障碍人口> 60；在此中，ARMD是损害的最大原因。 ARMD的主要特征是无法在光/黑暗（L/D）之间进行适应，从而导致功能性视觉损失在室内/室外。目前尚无适用于所有患者的ARMD的经过证明的，实用的，无创的或外科治疗的方法。当前高度不足的补救措施：（1）在L/d之间迅速涂上/脱离墨镜的多层太阳镜。 （2）V。慢切换光色素（需要激活的紫外线，不完整的切换25-30 s，完成3-5分钟，在汽车/室内不工作）。 （3）昂贵的抗血管生成药物，低视觉艾滋病，光动力疗法（v。LimitedRelief）。 （4）手术，主要用于“终阶段”臂，例如：望远镜植入物（仅部分视觉）；激光光凝（仅适用于非饲养臂）；下视网膜下手术（成功有限）。解决方案将大大提高40％> 60岁的成年人的生活质量/福祉，以及患有其他年龄相关疾病的人，例如糖尿病性视网膜病，角膜营养不良，色素性视网膜炎，瓦格纳综合征，视网膜施术。在较早的工作中，我们的小组在亚特兰大VA中心进行了大量研究> 60名ARMD退伍军人，这表明他们可以从基于液晶（LCS）的快速变形（<5 s）电致（EC）玻璃杯中受益，而多个太阳镜/ - 光染色体；但是，LC眼镜有严重的缺点。在目前的第一阶段，证明了基于导电聚合物（CP）的突破性EC技术：（1）完全匹配，合适的CP，产生典型的L/D对比度为70％/10％（380-760 nm，行业 - 标准标准算法）。 （2）具有算法的廉价（<$ 3）控制器的切换时间> 5倍，比传统的电压控制速度快5倍（l-> d 2至4 s，d-> l 1 s）;完全 自动化的光电传感器控制。 （3）V。薄，柔性，耐用。 （4）循环> 10^5个周期。 （5）出色的光学记忆。 （6）V。低功率（15 UW/CM2，+/- 3.0 VDC）。 （7）EST。 <$ 27/对。 （8）高电流电位开发（<$ 200/单位），大大降低了制造成本。拟议的工作将：（1）完整的最终技术改进（主要是较低的耐药性，较薄的ITO底物可显着增强切换时间和L/D对比度）。 （2）制造3种不同产品设计的原型。 （3）通过对亚特兰大VA中心的ARMD患者进行测试（75名受试者> 55岁，ARMD +其他与年龄有关的眼部疾病）进行优化。 （4）进一步的小型化，制造控制器，电池。 （5）完成初始生产。优化。研究。 （6）初始飞行员 植物，每月100玻璃对。 （7）扩大规模：每月1000至10,000眼镜，解决自动化问题，估计产品成本。 （8）与选定合同制造商，营销合作建立关系。成功的II期还将产生可以取代整个光致变色市场的电色素学，从而大大降低ARMD太阳镜的成本。与亚特兰大VA Rehab R＆D CTR的联合努力。对于老化的视力丧失，两家工业自动化公司，几个眼镜分销商。